Agios Pharmaceuticals Inc (AGIO)

25.77 +0.49 (+1.94%) USD  |  NASDAQ  |  Jun 01, 14:07
More

Agios Pharmaceuticals News

News

Headline
Wire
Time (ET)
Agios Pharmaceuticals (AGIO): Strong Industry, Solid Earnings Estimate Revisions
Yahoo
05/30 09:45
Does Agios Pharmaceuticals (AGIO) Have the Potential to Rally 34.83% as Wall Street Analysts Expect?
Yahoo
05/25 09:55
Agios Appoints Catherine Owen to Board of Directors
Yahoo
05/25 07:00
Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress
Yahoo
05/11 10:00
Wall Street Analysts Predict a 42.46% Upside in Agios Pharmaceuticals (AGIO): Here's What You Should Know
Yahoo
05/09 09:55
An Intrinsic Calculation For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Suggests It's 48% Undervalued
Yahoo
05/08 07:55
Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Yahoo
05/05 10:50
Q1 2023 Agios Pharmaceuticals Inc Earnings Call
Yahoo
05/04 23:23
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
Yahoo
05/04 08:25
-- Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Posts Q1 Revenue $5.6M
MT Newswires
05/04 07:07
Agios Pharmaceuticals GAAP EPS of -$1.47 beats by $0.23, revenue of $5.6M beats by $0.37M
SA Breaking News
05/04 07:07
Agios Reports Business Highlights and First Quarter 2023 Financial Results
Globe Newswire
05/04 07:00
Agios Pharmaceuticals Q1 2023 Earnings Preview
SA Breaking News
05/03 13:42
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023
Globe Newswire
04/25 07:00
Agios Appoints Jeffrey Capello to Board of Directors
Yahoo
04/19 07:00
Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023
Globe Newswire
04/13 07:00
Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero
PR Newswire
04/12 08:00
7 Biotech Stocks to Buy for 100% Returns
Yahoo
04/09 13:19
Insider Sell: Agios Pharmaceuticals
MT Newswires
04/05 16:09
Agios Publishes 2023 Environmental, Social and Governance (ESG) Report
Yahoo
04/03 07:00
Top Stocks for April 2023
Yahoo
03/27 16:49
Insider Sell: Agios Pharmaceuticals
MT Newswires
03/15 17:15
7 Biotech Stocks That Could Be the Next Big Thing
Yahoo
03/15 11:44
We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
Yahoo
03/11 09:10
TipRanks ‘Perfect 10’ List: These 2 Healthcare Stocks Look Compelling at Current Levels
Yahoo
03/05 05:20
Agios to Participate in March Investor Conferences
Globe Newswire
03/02 08:26
Insider Sell: Agios Pharmaceuticals
MT Newswires
03/01 16:23
Agios Launches “Red Cell Revolution” in Recognition of Rare Disease Day
Globe Newswire
02/28 07:00
Agios Pharmaceuticals Swings to Q4 Net Income
MT Newswires
02/23 09:17
Notable earnings before Thursday's open
SA Breaking News
02/22 10:41
Insider Sell: Agios Pharmaceuticals
MT Newswires
02/15 16:14
--Piper Sandler Starts Agios Pharmaceuticals at Overweight With $41 Price Target
MT Newswires
02/03 07:27
Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023
Globe Newswire
02/02 07:00
Insider Sell: Agios Pharmaceuticals
MT Newswires
02/01 16:15
Insider Sell: Agios Pharmaceuticals
MT Newswires
01/19 16:08
Agios rare blood disorder drug Pyrukynd sustains benefits in patients in long term data
SA Breaking News
12/12 04:47
Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition
Globe Newswire
12/11 19:00
JPMorgan Chase Adjusts Price Target on Agios Pharmaceuticals to $33 From $48, Maintains Neutral Rating
MT Newswires
12/01 09:41
--Goldman Sachs Upgrades Agios Pharmaceuticals to Neutral from Sell, Lifts Price Target to $32 From $17
MT Newswires
11/17 10:26
Agios granted EU approval for Pyrukynd in pyruvate kinase deficiency
SA Breaking News
11/11 07:19
PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
Globe Newswire
11/10 16:01
--RBC Trims Price Target on Agios Pharmaceuticals to $43 From $44, Maintains Outperform Rating
MT Newswires
11/04 08:17
-- Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Posts Q3 Revenue $3.5M
MT Newswires
11/03 07:06
Agios Reports Business Highlights and Third Quarter 2022 Financial Results
Globe Newswire
11/03 07:00
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
Globe Newswire
10/27 16:01
Agios Pharmaceuticals' CFO Resigns, Replacement Named
MT Newswires
09/19 07:17
Agios Appoints Cecilia Jones as Chief Financial Officer
Globe Newswire
09/19 07:00
Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
Globe Newswire
09/16 06:41
Agios to Participate in September Investor Conferences
Globe Newswire
08/24 07:00
Agios Pharmaceuticals Says Positive Findings From Phase 3 Trial of FDA-Approved Blood Disorder Drug Now Published
MT Newswires
08/19 03:41
Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
Globe Newswire
08/18 18:35
Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors
Globe Newswire
08/15 08:00
Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia
Globe Newswire
08/11 18:35
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer
Globe Newswire
08/08 18:36
--RBC Cuts Price Target on Agios Pharmaceuticals to $44 From $48, Maintains Outperform Rating
MT Newswires
08/05 07:36
Agios stock rises as Q2 sees new drug Pyrukynd bring in revenue
SA Breaking News
08/04 11:46
Agios Pharmaceuticals Q2 Beats Expectations, Sees No Need to Raise Equity; Shares Rise Sharply
MT Newswires
08/04 10:49
-- Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Posts Q2 Revenue $5.6M
MT Newswires
08/04 07:00
--SVB Securities Upgrades Agios Pharmaceuticals to Outperform from Market Perform, Keeps $33 Price Target
MT Newswires
07/27 08:50
Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022
Globe Newswire
07/14 07:00
Agios Pharmaceuticals CEO Jackie Fouse to Transition to Board Chair; Brian Goff to Take Over as CEO
MT Newswires
07/12 16:17
Agios Pharmaceuticals appoints new board chair, CEO
SA Breaking News
07/12 16:09
--RBC Lifts Price Target on Agios Pharmaceuticals to $48 From $47, Maintains Outperform Rating
MT Newswires
07/07 09:12
Centogene Expands Pyrukynd Development Partnership With Agios to Treat Children With Rare Blood Disease
MT Newswires
06/13 06:58
Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress
Globe Newswire
06/10 10:30
Goldman Sachs Adjusts Agios Pharmaceuticals' Price Target to $16 from $20, Keeps Sell Rating
MT Newswires
05/24 10:32
SVB Securities Adjusts Price Target for Agios Pharmaceuticals to $33 From $30, Maintains Market Perform Rating
MT Newswires
05/17 11:32
Agios Pharmaceuticals to Transition to Exploratory Research, Drug Discovery
MT Newswires
05/16 16:51
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022
Globe Newswire
05/10 07:00
--RBC Cuts Price Target on Agios Pharmaceuticals to $47 From $67, Maintains Outperform Rating
MT Newswires
05/06 08:07
-- Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Posts Q1 Revenue $832,000, vs. Street Est of $2.71M
MT Newswires
05/05 07:05
Agios Reports Business Highlights and First Quarter 2022 Financial Results
Globe Newswire
05/05 07:00
Notable earnings before Thursday's open
SA Breaking News
05/04 11:07
Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022
Globe Newswire
04/21 07:00
Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
Globe Newswire
04/14 08:34
--HC Wainwright Lowers Agios Pharmaceuticals Price Target to $96 From $98, Maintains Buy Rating
MT Newswires
03/03 11:00
Agios to Participate in March Investor Conferences
Globe Newswire
02/28 07:00
--RBC Raises Price Target on Agios Pharmaceuticals to $67 From $61, Maintains Outperform Rating
MT Newswires
02/25 07:59
Agios Pharmaceuticals Q4 Net Loss Per Share Widens
MT Newswires
02/24 09:45
Agios Reports Fourth Quarter and Full Year 2021 Financial Results
Globe Newswire
02/24 07:00
Agios Pharmaceuticals Q4 2021 Earnings Preview
SA Breaking News
02/23 14:16
SVB Leerink Adjusts Agios Pharmaceuticals' Price Target to $30 from $32, Maintains Market Perform Rating
MT Newswires
02/22 12:50
HC Wainwright Adjusts Agios Pharmaceuticals' Price Target to $98 from $95, Keeps Buy Rating
MT Newswires
02/18 11:39
Agios Pyrukynd for rare blood disorder gets US FDA approval
SA Breaking News
02/18 06:00
Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency
Globe Newswire
02/17 15:41
Canaccord Genuity Adjusts Agios Pharmaceuticals' Price Target to $44 from $52, Maintains Buy Rating
MT Newswires
02/16 13:58
Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases
Globe Newswire
01/10 07:00
Canaccord Genuity Adjusts Agios Pharmaceuticals' Price Target to $52 From $65, Keeps Buy Rating
MT Newswires
12/20 09:31
Agios presents mitapivat long-term data in PK deficiency at ASH 2021
SA Breaking News
12/14 03:39
Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition
Globe Newswire
12/13 18:15
Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at 63rd ASH Annual Meeting and Exposition
Globe Newswire
12/13 07:00
BofA Securities Starts Agios Pharmaceuticals at Buy With $54 Price Target
MT Newswires
12/03 06:12
Agios Appoints Richa Poddar as Chief Commercial Officer
Globe Newswire
11/15 16:01
--HC Wainwright Adjusts Agios Pharmaceuticals' Price Target to $95 from $93, Keeps Buy Rating
MT Newswires
11/04 12:33
Agios Pharmaceuticals Q3 Net Loss Per Share Widens
MT Newswires
11/03 08:26
Agios To Present at September Investor Conferences
Globe Newswire
08/30 07:00
Agios Says US FDA Accepts Mitapivat New Drug Application for Priority Review
MT Newswires
08/17 16:15
Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
Globe Newswire
08/17 16:01
--HC Wainwright Adjusts Agios Pharmaceuticals' Price Target to $93 From $88, Reiterates Buy Rating
MT Newswires
07/30 11:53
--Goldman Sachs Cuts Agios Pharmaceuticals to Sell From Neutral, Price Target to $39 From $58
MT Newswires
07/30 08:50
Agios Pharmaceuticals Posts Wider Net Loss in Q2
MT Newswires
07/29 14:37
Agios Pharmaceuticals EPS misses by $0.12
SA Breaking News
07/29 07:09
Notable earnings before Thursday's open
SA Breaking News
07/28 10:01
Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021
Globe Newswire
07/15 07:00
Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
Globe Newswire
06/28 07:00
Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency
Globe Newswire
06/22 07:00
Agios submits mitapivat application in U.S. for pyruvate kinase deficiency
SA Breaking News
06/21 08:21
Agios Pharmaceuticals Submits Rare Disease Therapy Application to US FDA
MT Newswires
06/21 07:53
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
Globe Newswire
06/21 07:00
Agios's mitapivat shows positive action in Phase 2 non-transfusion-dependent thalassemia study
SA Breaking News
06/11 08:39
Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress
Globe Newswire
06/11 03:00
Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress
Globe Newswire
06/11 03:00
HC Wainwright Starts Agios Pharmaceuticals at Buy With $88 Price Target
MT Newswires
06/10 08:47
Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress
Globe Newswire
05/12 10:00
--Canaccord Genuity Adjusts Price Target on Agios Pharmaceuticals to $65 From $57, Maintains Buy Rating
MT Newswires
04/30 12:08
--RBC Capital Adjusts Agios Pharmaceuticals PT to $61 From $59, Maintains Outperform Rating
MT Newswires
04/30 09:12
--Barclays Adjusts Price Target on Agios Pharmaceuticals to $70 From $65, Maintains Overweight Rating
MT Newswires
04/30 08:34
Agios Pharmaceuticals' Q1 Loss Widens
MT Newswires
04/29 09:45
Agios posts wider Q1 loss as R&D expenses rise
SA Breaking News
04/29 08:04
-- Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Posts Q1 Loss $-1.31
MT Newswires
04/29 07:12
Agios Reports Business Highlights and First Quarter 2021 Financial Results
Globe Newswire
04/29 07:00
Notable earnings before Thursday's open
SA Breaking News
04/28 12:17
Agios Pharmaceuticals Q1 2021 Earnings Preview
SA Breaking News
04/28 12:16
Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021
Globe Newswire
04/15 07:00
Agios to repurchase $345 million stock from Bristol-Myers
SA Breaking News
04/01 14:13
Agios Pharmaceuticals Closes Oncology Business Sale to Servier
MT Newswires
04/01 08:02
Agios Announces Closing of Oncology Business Sale to Servier
Globe Newswire
04/01 07:00
Sector Update: Health Care Stocks Surging Just Ahead of Friday Close
MT Newswires
03/26 15:54
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
MT Newswires
03/26 09:07
Agios Shareholders Approve Divestment of Oncology Business to Servier
MT Newswires
03/26 04:15
Agios shareholders approve oncology business sale to Servier Pharmaceuticals
SA Breaking News
03/25 16:14
Agios Shareholders Approve Sale of Oncology Business to Servier
Globe Newswire
03/25 16:01
Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease
Globe Newswire
03/18 07:00
Agios cut to neutral at JPM citing valuation and lack of notable catalysts
SA Breaking News
03/01 15:46
Agios Pharmaceuticals Submits New Drug Application for Treatment of Rare and Aggressive Bile Duct Cancer
MT Newswires
03/01 15:09
Agios submits TIBSOVO marketing application to FDA
SA Breaking News
03/01 08:00
Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
Globe Newswire
03/01 07:00
--Analyst Actions: JPMorgan Downgrades Agios Pharmaceuticals to Neutral From Overweight; Price Target is $54
MT Newswires
03/01 06:41
Premarket analyst action - healthcare
SA Breaking News
02/26 09:27
--Analyst Actions: SVB Leerink Downgrades Agios Pharmaceuticals to Market Perform From Outperform; Price Target is $50
MT Newswires
02/26 09:04
Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias
Globe Newswire
02/26 07:00
Sector Update: Health Care Stocks Fall Thursday but Mostly Resist Steep Slide
MT Newswires
02/25 15:37
Sector Update: Health Care Stocks Starting to Lose More Ground This Afternoon
MT Newswires
02/25 13:09
Agios Pharmaceuticals' Q4 Loss Narrows, Revenue Rises
MT Newswires
02/25 09:08
Agios Pharmaceuticals EPS misses by $0.10, beats on revenue
SA Breaking News
02/25 07:13
-- Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Reports Q4 Revenue $44M
MT Newswires
02/25 07:08
Agios Reports Fourth Quarter and Full Year 2020 Financial Results
Globe Newswire
02/25 07:00
Notable earnings before Thursday's open
SA Breaking News
02/24 12:49
Agios Pharmaceuticals Q4 2020 Earnings Preview
SA Breaking News
02/24 11:55
Agios to Present at March Investor Conferences
Globe Newswire
02/23 07:00
Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021
Globe Newswire
02/11 07:00
Analyst Actions: SVB Leerink Adjusts Agios Pharmaceuticals' Price Target to $55 from $51, Keeps Outperform Rating
MT Newswires
01/27 11:23
BBBY, IMMP, TTOO and VIR among after-hours movers
SA Breaking News
01/26 17:58
Agios Pharmaceuticals Phase 3 Study of Pyruvate Kinase Deficiency Produces 'Statistically Significant' Results
MT Newswires
01/26 16:20
Agios posts positive data from phase 3 ACTIVATE-T trial of mitapivat
SA Breaking News
01/26 16:09
Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused
Globe Newswire
01/26 16:01
Agios reports final data analysis in late-stage trial for rare cancer
SA Breaking News
01/17 13:19
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
Globe Newswire
01/17 10:00
Agios highlights 2021 milestones, sees filing for sickle cell drug U.S. approval in Q2
SA Breaking News
01/12 02:04
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
Globe Newswire
01/11 07:00
Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
Globe Newswire
01/05 07:00
Analyst Actions: Canaccord Adjusts Agios Pharmaceuticals' Price Target to $57 From $70, Keeps Buy Rating
MT Newswires
12/28 10:26
Agios Pharmaceuticals' Oncology Business Sale to Provide Capital for Mitapivat's Clinical Development, Oppenheimer Says
MT Newswires
12/22 10:57
Analyst Actions: RBC Capital Adjusts Price Target on Agios Pharmaceuticals to $59 From $66, Maintains Outperform Rating
MT Newswires
12/22 07:51
Sector Update: Health Care Shares Ending Lower Monday Afternoon
MT Newswires
12/21 16:01
Sector Update: Health Care Stocks Slip in Monday Trading
MT Newswires
12/21 13:59
AGIO, NK, RP and QURE among midday movers
SA Breaking News
12/21 12:42
EyeGate Pharmaceuticals, Editas Medicine leads healthcare gainers; Scopus BioPharma, uniQure among major losers
SA Breaking News
12/21 11:03
Thinking about buying stock in Agios Pharmaceuticals, Clovis Oncology, Aqua Metals, Cocrystal Pharma, or Luminar Technologies?
PR Newswire
12/21 09:31
Sector Update: Health Care Stocks Trade Lower Premarket Monday
MT Newswires
12/21 09:22
Sector Update: Health Care
MT Newswires
12/21 08:55
AJRD, AJIO, NK and LAZR among premarket gainers
SA Breaking News
12/21 08:26
Agios Pharmaceuticals Sells Oncology Portfolio Servier for Up to $2 Billion; Shares Jump
MT Newswires
12/21 08:11
Servier to buy Agios Pharma's oncology portfolio for $2B
SA Breaking News
12/21 07:51
Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties
Globe Newswire
12/21 07:00
Analyst Actions: SVB Leerink Adjusts Agios Pharmaceuticals' Price Target to $61 from $67, Keeps Outperform Rating
MT Newswires
12/09 10:14
IBIO, SFIX, ARCT and LXRX among midday movers
SA Breaking News
12/08 12:40
Agios's mitapivat data in sickle cell disappoints at ASH presentation
SA Breaking News
12/08 11:40
Curis, Lexicon Pharmaceuticals leads healthcare gainers; Obalon Therapeutics, Arcturus Therapeutics among major losers
SA Breaking News
12/08 11:00
Agios Pharmaceuticals Phase 1 Study of Sickle Cell Disease Shows Promising Results
MT Newswires
12/07 16:59
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
Globe Newswire
12/07 16:30
Agios Pharmaceuticals' Phase 3 Trial of Blood Disorder Drug Achieves Primary Endpoint
MT Newswires
12/01 09:49
Agios' mitapivat successful in late-stage study in rare blood disorder
SA Breaking News
12/01 08:11
Agios Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved Its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
Globe Newswire
12/01 07:00
Agios Pharmaceuticals Launches Hereditary Anemias Genetic Testing Program
MT Newswires
11/30 12:50
Agios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary Anemias
Globe Newswire
11/30 07:00
Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020
Globe Newswire
11/25 07:00
Analyst Actions: Barclays Adjusts Agios Pharmaceuticals' Price Target to $50 from $46, Keeps Overweight Rating
MT Newswires
11/20 10:35
--Analyst Actions: Cantor Fitzgerald Adjusts Agios Pharmaceuticals PT to $79 From $68, Maintains Overweight Rating
MT Newswires
11/19 12:41
Agios's mitapivat an Orphan Drug in U.S. for sickle cell disease
SA Breaking News
11/12 17:06
Agios Pharmaceuticals Receives FDA Orphan Drug Designation for Mitapivat for Treatment of Sickle Cell Disease
MT Newswires
11/12 16:51
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease
Globe Newswire
11/12 16:30
Analyst Actions: RBC Capital Adjusts Agios Pharmaceuticals' Price Target to $64 From $68, Maintains Outperform Rating
MT Newswires
11/06 07:38
Agios Pharmaceuticals Q3 Loss Narrows, Revenue Increases
MT Newswires
11/05 08:44
-- Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Posts Q3 EPS $-1.43
MT Newswires
11/05 07:22
-- Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Posts Q3 Revenue $34.7M
MT Newswires
11/05 07:22
Agios Pharmaceuticals EPS misses by $0.06, misses on revenue
SA Breaking News
11/05 07:10
Agios Reports Business Highlights and Third Quarter 2020 Financial Results
Globe Newswire
11/05 07:00
Agios Pharmaceuticals Q3 Earnings Preview
SA Breaking News
11/04 11:51
Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting
Globe Newswire
11/04 11:45
Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020
Globe Newswire
10/29 16:01
Analyst Actions: Barclays Upgrades Agios Pharmaceuticals to Overweight From Equal-Weight; Price Target is $46
MT Newswires
10/22 07:08
Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020
Globe Newswire
10/22 07:00
--Analyst Actions: Needham Adjusts Price Target for Agios Pharmaceuticals to $69 From $71, Maintains Buy Rating
MT Newswires
10/19 15:02
Analyst Actions: SVB Leerink Adjusts Agios Pharmaceuticals' Price Target to $67 From $72, Keeps Outperform Rating
MT Newswires
10/19 11:47
Analyst Actions: Canaccord Genuity Adjusts Agios Pharmaceuticals' Price Target to $70 From $72, Reiterates Buy Rating
MT Newswires
10/19 10:57
Analyst Actions: Piper Sandler Adjusts Price Target on Agios Pharmaceuticals to $73 From $80, Maintains Overweight Rating
MT Newswires
10/19 10:19
FISV, TCOM, FLDM and SELB among after-hours movers
SA Breaking News
10/16 17:42
Agios Pharma Pulls Tibsovo Application for Bone Marrow Cancer in Europe -- Stock Slides 6% After-Hours
MT Newswires
10/16 16:17
Agios falls after pulling European marketing application for Tibsovo
SA Breaking News
10/16 16:14
Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia
Globe Newswire
10/16 16:01
Agios Says Overall Survival Data from Phase 3 Study of Bile Duct Cancer Therapy Not Statistically Significant
MT Newswires
09/21 11:20
Agios' TIBSOVO improves OS, but not statistically significant vs. placebo in bile duct cancer
SA Breaking News
09/21 07:23
Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients
Globe Newswire
09/21 07:00
New finance chief at Agios Pharmaceuticals
SA Breaking News
09/09 06:24
Chief Legal Officer to Become CFO at Agios Pharmaceuticals
MT Newswires
09/08 16:17
Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs
Globe Newswire
09/08 16:01
Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020
Globe Newswire
08/27 07:00
Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020
Globe Newswire
08/06 07:00
Analyst Actions: RBC Capital Lifts Agios Pharmaceuticals' Price Target to $68 From $66, Maintains Outperform Rating
MT Newswires
07/31 07:25
-- Earnings Flash (AGIO) AGIOS PHARMACEUTICALS INC. Reports Q2 Revenue $37.3M
MT Newswires
07/30 07:13
Agios Reports Business Highlights and Second Quarter 2020 Financial Results
Globe Newswire
07/30 07:00
Notable earnings before Thursday's open
SA Breaking News
07/29 12:32
Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020
Globe Newswire
07/16 07:01
Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020
Globe Newswire
06/17 16:01
Analyst Actions: SVB Leerink Lifts Agios Pharmaceuticals PT to $72 From $70, Maintains Outperform Rating
MT Newswires
06/15 11:22
Thermo Fisher Scientific Wins FDA Breakthrough Therapy Designation for Brain Tumors Test
MT Newswires
06/15 11:02
Analyst Actions: Guggenheim Raises Price Target on Agios Pharmaceuticals to $66 From $60, Reiterates Buy Rating
MT Newswires
06/15 09:44
Analyst Actions: Citigroup Lifts Price Target on Agios Pharmaceuticals to $75 From $64, Maintains Buy Rating
MT Newswires
06/15 08:26
Thermo Fisher nabs accelerated review in U.S. for glioma test
SA Breaking News
06/15 07:54
Sector Update: Health Care Stocks Gain Premarket Friday
MT Newswires
06/12 09:12
Agios' mitapivat demonstrates sustained hemoglobin responses in thalassemia patients
SA Breaking News
06/12 07:23
Agios Sells Rights to Royalty Pharma on Idhifa Global Sales, Milestone Payments for $255 Million
MT Newswires
06/12 07:14
Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty
Globe Newswire
06/12 06:30
Agios reports positive mitapivat data in sickle cell disease
SA Breaking News
06/12 06:23
Agios Pharmaceuticals Releases Positive Interim Data From Clinical Trials of Blood Disorder Drug Mitapivat
MT Newswires
06/12 06:18
Agios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell Disease
Globe Newswire
06/12 02:30
Agios First-in Class PKR Activator Mitapivat Demonstrates Sustained Hemoglobin Responses in Non-transfusion-dependent α- and β-Thalassemia in Phase 2 Study
Globe Newswire
06/12 02:30
Thermo Fisher teams up with Agios on second companion diagnostic
SA Breaking News
06/09 07:45
FDA grants orphan drug designation to Agios's mitapivat for thalassemia
SA Breaking News
06/08 17:09
Agios Wins US FDA Orphan Drug Designation for Mitapivat for Treatment of Thalassemia
MT Newswires
06/08 16:15
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia
Globe Newswire
06/08 16:01
Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma
Globe Newswire
05/29 08:00
Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients
Globe Newswire
05/19 07:00
Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress
Globe Newswire
05/14 09:41
Agios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the American Society of Clinical Oncology Annual Meeting
Globe Newswire
05/13 17:01
Agios to Present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020
Globe Newswire
05/12 07:00
Piper Sandler says "buy the dip" in Agios ahead of key data readouts
SA Breaking News
05/11 13:20
--Analyst Actions: RBC Capital Cuts Agios Pharmaceuticals' Price Target to $66 From $69, Keeps Outperform Rating
MT Newswires
05/01 09:00
Agios Pharmaceuticals Posts Narrower Q1 Loss, Higher Revenue
MT Newswires
04/30 11:23